Coloplast A/S

WBAG:COLO Stock Report

Market Cap: €24.2b

Coloplast Valuation

Is COLO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of COLO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: COLO (€107.35) is trading below our estimate of fair value (€198.23)

Significantly Below Fair Value: COLO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COLO?

Key metric: As COLO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for COLO. This is calculated by dividing COLO's market cap by their current earnings.
What is COLO's PE Ratio?
PE Ratio35.7x
EarningsDKK 5.05b
Market CapDKK 180.33b

Price to Earnings Ratio vs Peers

How does COLO's PE Ratio compare to its peers?

The above table shows the PE ratio for COLO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average38.8x
COO Cooper Companies
47x19.4%US$18.9b
ALC Alcon
36.5x9.9%CHF 37.9b
7741 HOYA
35.7x11.4%JP¥7.0t
ALGN Align Technology
36x17.5%US$17.1b
COLO Coloplast
35.7x11.8%€180.3b

Price-To-Earnings vs Peers: COLO is good value based on its Price-To-Earnings Ratio (35.7x) compared to the peer average (38.8x).

Price to Earnings Ratio vs Industry

How does COLO's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
COLO 35.7xIndustry Avg. 29.5xNo. of Companies9PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: COLO is expensive based on its Price-To-Earnings Ratio (35.7x) compared to the European Medical Equipment industry average (29.4x).

Price to Earnings Ratio vs Fair Ratio

What is COLO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COLO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio35.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate COLO's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COLO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€107.35
€124.13
+15.6%
9.5%€138.06€93.83n/a21
Dec ’25€118.45
€123.94
+4.6%
9.4%€138.06€93.82n/a21
Nov ’25€116.75
€122.49
+4.9%
11.0%€140.82€93.88n/a21
Oct ’25€117.55
€122.54
+4.2%
11.0%€142.18€93.89n/a20
Sep ’25€123.40
€122.17
-1.0%
11.3%€142.09€93.84n/a20
Aug ’25€119.75
€121.42
+1.4%
11.0%€142.07€95.16n/a20
Jul ’25€111.80
€120.02
+7.4%
10.5%€142.08€95.17n/a20
Jun ’25€110.60
€121.95
+10.3%
10.2%€142.06€95.16n/a19
May ’25€113.10
€122.93
+8.7%
10.9%€142.09€93.83n/a19
Apr ’25€123.85
€120.32
-2.9%
10.3%€142.13€93.86n/a19
Mar ’25€122.65
€116.96
-4.6%
10.1%€134.16€93.91n/a19
Feb ’25€107.20
€110.46
+3.0%
9.8%€129.01€84.62n/a19
Jan ’25€104.15
€109.56
+5.2%
10.3%€129.07€84.66n/a18
Dec ’24€105.95
€109.69
+3.5%
10.1%€129.05€84.65€118.4518
Nov ’24€100.45
€113.71
+13.2%
9.2%€131.29€91.90€116.7518
Oct ’24€100.55
€116.05
+15.4%
9.9%€134.12€92.01€117.5517
Sep ’24€105.90
€121.79
+15.0%
10.1%€143.59€96.62€123.4015
Aug ’24€113.50
€124.66
+9.8%
9.9%€143.60€96.63€119.7516
Jul ’24€114.75
€122.90
+7.1%
11.0%€143.65€92.63€111.8016
Jun ’24€117.45
€122.95
+4.7%
11.0%€143.71€92.67€110.6016
May ’24€130.65
€122.53
-6.2%
10.0%€140.25€92.61€113.1016
Apr ’24€121.40
€121.15
-0.2%
9.8%€140.26€92.61€123.8516
Mar ’24€107.25
€121.26
+13.1%
10.2%€140.31€92.64€122.6515
Feb ’24€113.75
€121.99
+7.2%
9.7%€140.50€92.77€107.2015
Jan ’24€111.25
€123.56
+11.1%
7.7%€140.52€107.31€104.1515
Dec ’23€114.55
€126.00
+10.0%
11.4%€164.59€107.31€105.9514

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 04:52
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Coloplast A/S is covered by 49 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Morten LarsenABG Sundal Collier
Kamla SinghAlphaValue
Robert BateBarclays